VRDN vs. GH, OPCH, RDNT, SHC, BTSG, SGRY, VCYT, LFST, CON, and PRVA
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), Sotera Health (SHC), BrightSpring Health Services (BTSG), Surgery Partners (SGRY), Veracyte (VCYT), LifeStance Health Group (LFST), Concentra Group Holdings Parent (CON), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry.
Viridian Therapeutics vs.
Viridian Therapeutics (NASDAQ:VRDN) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Guardant Health has a net margin of -74.02% compared to Viridian Therapeutics' net margin of -85,127.16%. Viridian Therapeutics' return on equity of -70.12% beat Guardant Health's return on equity.
Guardant Health received 210 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 78.72% of users gave Viridian Therapeutics an outperform vote while only 70.30% of users gave Guardant Health an outperform vote.
92.6% of Guardant Health shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Viridian Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.
In the previous week, Guardant Health had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 10 mentions for Guardant Health and 2 mentions for Viridian Therapeutics. Guardant Health's average media sentiment score of 1.18 beat Viridian Therapeutics' score of 0.86 indicating that Guardant Health is being referred to more favorably in the news media.
Viridian Therapeutics currently has a consensus price target of $35.70, suggesting a potential upside of 114.80%. Guardant Health has a consensus price target of $42.63, suggesting a potential downside of 10.07%. Given Viridian Therapeutics' higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Guardant Health.
Viridian Therapeutics has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Guardant Health beats Viridian Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VRDN) was last updated on 2/21/2025 by MarketBeat.com Staff
